Company News »

Epizyme Announces Notices of Allowance for US Patent Applications Covering PRMT5 Inhibitors and Methods of Cancer Treatment with PRMT5 Inhibitors

Business Wire
Share on StockTwits
Published on

Epizyme, Inc. (NASDAQ:EPZM) , a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the US Patent and Trademark Office has granted Notices of Allowance for US Patent Applications, Nos. 14/136,551 and 14/136,738, both entitled “PRMT5 Inhibitors and Uses Thereof.” The allowed claims cover inhibitors of PRMT5 and methods of cancer treatment with PRMT5 inhibitors. PRMT5 is implicated in several cancers, including blood cancers.

Epizyme also announced the publication of 10 patent applications covering chemical matter targeting several additional HMTs: CARM1, PRMT1, PRMT3, PRMT6 and PRMT8. These additional HMT targets are implicated in a variety of solid tumors and hematologic malignancies.

“These notices of allowance and publications further solidify our leadership position in the HMT space, and we continue to advance our dominant intellectual property position. Epizyme now has patents and patent applications for 13 of the 20 prioritized targets that comprise the Company’s pioneering HMT platform, covering therapeutic and diagnostic methods, combination therapy methods and pharmaceutical compositions,” said Robert Gould, Ph.D., President and Chief Executive Officer, Epizyme. “We believe these patents and pending applications place us in the strongest possible position to build our company over the long-term and accelerate our efforts to bring life-saving drugs to patients.”

About Epizyme, Inc.

Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme’s targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

Share on StockTwits